A Sánchez Toranzo// Farmacología. De la molécula al paciente. Farmacología endócrina y del metabolismo. Parte 2 Bibliografía Brashier, D. B. S., Sharma, a K., Dahiya, N., Singh, S. K., & Khadka, A. 2014. Lorcaserin: A novel antiobesity drug. Journal of Pharmacology & Pharmacotherapeutics; 5(2):175–8. Bray GA, Ryan DH. 2014 Apr. Update on obesity pharmacotherapy. Ann N Y Acad Sci; 1311:1- 13. Brunton LL, Chabner BA, Knollmann BC. 2012. Goodman & Gilman Las Bases Farmacológicas de la Terapéutica. Mc Graw Hill´s; 12a edición. Chung, J. Y., Jang, S. B., Lee, Y. J., Park, M. S., & Park, K. 2011. Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. Journal of Clinical Pharmacology, 51(1):53–9. Comerma-Steffensen S, Grann M, Andersen CU, Rungby J, Simonsen U. 2014 May; Cardiovascular effects of current and future anti-obesity drugs. Curr Vasc Pharmacol, 12(3):493-504. Fleming JW, McClendon KS, Riche DM. 2013 Jul-Aug. New obesity agents: lorcaserin and phentermine/topiramate. Ann Pharmacother; 47(7-8):1007-16. Flórez J, Amijo JA.Florez, Farmacología Humana. 2008. África Mediavilla, Masson. 5a Edición. Fulp A, Bortoff K, Zhang Y, Snyder R, Fennell T, Marusich JA, Wiley JL, Seltzman H, Maitra R. 2013 Oct 24. Peripherally selective diphenyl purine antagonist of the CB1 receptor. J Med Chem; 56(20):8066-72. Hofbauer, K. G., Nicholson, J. R., & Boss, O. 2007. The obesity epidemic: current and future pharmacological treatments. Annual Review of Pharmacology and Toxicology; 47:565–92. Hruba L, McMahon LR. 2014 Mar. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys. Eur J Pharmacol; 727:35-42. Jager G, Witkamp RF. 2014 Jun. The endocannabinoid system and appetite: relevance for food reward. Nutr Res Rev; 27(1):172-85. Kaplan LM. 2010. Pharmacologic therapies for obesity. Gastroenterology Clinics of North America; 39(1):69–79. Katzung BG, Masters SB, Trevor AJ. 2009. Katsung, Basic & Clinical Pharmacology. Mc Graw Hill. 11th edition. Klumpers LE, Fridberg M, de Kam ML, Little PB, Jensen NO, Kleinloog HD, Elling CE, van Gerven JM. 2013 Dec. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol; 76(6):846-57. Leung WYS, Thomas GN, Chan JCN, Tomlinson B. 2003. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clinical Therapeutics; 25(1):58–80. Mahgerefteh B, Vigue M, Freestone Z, Silver S, Nguyen Q. 2013 Sep. New drug therapies for the treatment of overweight and obese patients. Am Health Drug Benefits; 6(7):423-30. Manning S, Pucci A, Finer N. 2014 May Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis; 5(3):135-48. Ng SY, Wilding JP. 2014 Aug. Liraglutide in the treatment of obesity. Expert Opin Biol Ther; 14(8):1215-24. Padwal RS, Majumdar SR. 2007. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet; 369(9555):71–77. Romano A, Coccurello R, Giacovazzo G, Bedse G, Moles A, Gaetani S. 2014. Oleoylethanolamide: a novel potential pharmacological alternative to cannabinoid antagonists for the control of appetite. Biomed Res Int; 2014:203425. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. 2000. Influence of topiramate in the regu- 136
GTHolzmann, CMUngaro, A Sánchez Toranzo // Farmacología de la obesidad lation of energy balance. Nutrition; 16:961–966. Sharma MK, Murumkar PR, Kanhed AM, Giridhar R, Yadav MR. 2014 May. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists. Eur J Med Chem; 22(79):298-339. Shin J., Gadde K. 2013. Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity. Diabetes Metab Syndr Obes; 6:131–139. Sweeting AN, Tabet E, Caterson ID, Markovic TP. 2014 Feb. Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate. Diabetes Metab Syndr Obes; 7:35- 44. Woloshin S, Schwartz LM. 2014 Apr. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings? JAMA Intern Med; 174(4):615-9. Zieher, Farmacología endócrina y metabólica, de la inflamación y el dolor, Porf. Dr. Luis M. Zieher editor, 3ra edición. EDITORIAL SCIENS 137
